Pharmacogenomics is one of the key aspects of personalized medicine, focusing on how an individual’s DNA affects the way they respond to medications. All individuals have different genetic make-up so they respond differently to the same medication.
Based on this insight, pharmacogenomics allows customized treatment for a wide range of health problems including; cardiovascular disease, Alzheimer’s disease, cancer, HIV/AIDS, and asthma.
Digital health platform Azova is partnering with OneOme to offer the RightMed comprehensive test through Azova’s platform. The RightMed test is a pharmacogenomics test that analyzes a patient’s DNA to help physicians and pharmacists predict which medications and dosages may work best for the patient, potentially leading to more effective prescriptions, fewer side effects, and less trial and error to find the right medication.
OneOme was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic.
OneOme is working to become the most cost-effective, comprehensive, pharmacogenomic solution backed by the strongest clinical evidence; provide friendly, actionable clinical results to every healthcare provider and patient; ensure results are always accessible as patients transition through the health system at different points of care.
The RightMed ($349) test now covers 27 genes and over 350 medications that are used to treat more than 30 medical conditions, including cancer, depression, anxiety, pain, cardiovascular disease, and more.
OneOme recently announced several significant enhancements to its product offering, including the addition of four new genes (HLA-A, HLA-B, CYP4F2, and CYP2C Cluster) and nine new medications to its RightMed® comprehensive test.
The addition of the HLA-A and HLA-B genes is significant because providers who order the RightMed test will now be able to identify patients who have alleles associated with an increased risk of severe hypersensitivity, hepatotoxicity, and cutaneous reactions, such as Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), induced by certain medications. SJS/TEN is a severe, life-threatening skin reaction, which is usually triggered by medications.